% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Nov 10, 2007 12:08 PM Flag

    Polymerase inhibitors' troubles

    The following paragraph is taken of from Feuerstein's blog posted this morning. There is a critical typo, so I post here.

    "Pharmasset has already partnered development of R7128 with Swiss drug firm Roche. So far, R7128 looks a lot better than Roche's internal hepatitis C candidate <<R6126>>. That drug, while showing impressive efficacy at the meeting, also has some gnarly side effects, including high rates of neutropenia (low white-blood-cell counts that can lead to infection) and thrombocytopenia (low platelet counts that increase the risk of bleeding)."

    My comments:

    R6126 highlighted above cannot be found in literature or by googling. This must be R1626 misstyped. This drug will go down the drain just as NM283 and HCV796 have done, and it will take a miracle for R7128 to pass the safety test.

    Moreover, this class of drugs does not have the synergy with IFN although the drug effects may be additive. Protease inhibitors are unique in that it foils the sabotage attempt on immunity by HCV protease without which HCV cannot survive. This immune evasion by HCV using its protease has been validated over and over by researchers in the past two years.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
83.23+3.52(+4.42%)Feb 12 4:00 PMEST